An in-patient or out-patient (male or female) and aged ≥18 years
A diagnosis of schizophrenia, DSM-5 (Diagnostic and Statistical Manual Diploma in Social Medicine-5)
Subjects must have the ability to effectively communicate with investigator, complete study related documents, comprehend the key components of the consent form and must provide written informed consent to participate in the study prior to any study specific assessments or procedures.
Patients are taking or will take atypical antipsychotics which include olanzapine, risperidone, aripiprazole.
Baseline PANSS Total Score ≥70
You may not be if
Participation in other clinical studies.
Known intolerance or lack of efficacy to olanzapine, risperidone or aripiprazole.
Use of clozapine within 28 days prior to randomization.
Other conditions which, in the investigator's judgment, render patients unsuitable for the clinical study.
Clareo Health | Validating and Optimizing Model of Antipsychotics Selection
